Please use this identifier to cite or link to this item: https://doi.org/10.3390/jcdd8100123
Title: Coronary heart disease (Chd) in elderly patients: Which drug to choose, ticagrelor and clopidogrel? a systematic review and meta-analysis of randomized controlled trials
Authors: Akkaif, MA
Sha’aban, A
Daud, NAA
Yunusa, I
Ng, ML 
Sk Abdul Kader, MA
Noor, DAM
Ibrahim, B
Issue Date: 1-Oct-2021
Publisher: MDPI AG
Citation: Akkaif, MA, Sha’aban, A, Daud, NAA, Yunusa, I, Ng, ML, Sk Abdul Kader, MA, Noor, DAM, Ibrahim, B (2021-10-01). Coronary heart disease (Chd) in elderly patients: Which drug to choose, ticagrelor and clopidogrel? a systematic review and meta-analysis of randomized controlled trials. Journal of Cardiovascular Development and Disease 8 (10) : 123-123. ScholarBank@NUS Repository. https://doi.org/10.3390/jcdd8100123
Abstract: Background: A new generation P2Y12 receptor inhibitor (ticagrelor) is recommended in current therapeutic guidelines to treat patients with coronary heart disease (CHD). However, it is unknown if ticagrelor is more effective than clopidogrel in elderly patients. Therefore, a systematic review was done to assess the effectiveness and safety of ticagrelor and clopidogrel in older patients with CHD to determine the appropriate antiplatelet treatment plan. Methodology: We performed a systematic review of randomized controlled trials (RCTs) to compare the effectiveness and safety of ticagrelor vs. clopidogrel in elderly patients with CHD. We selected eligible RCTs based on specified study criteria following a systematic search of PubMed and Scopus databases from January 2007 to May 2021. Primary efficacy outcomes assessed were major adverse cardiovascular events (MACEs), myocardial infarction (MI), stent thrombosis (ST), and all-cause death. The secondary outcome assessed was major bleeding events. We used RevMan 5.3 software to conduct a random-effects meta-analysis and estimated the pooled incidence and risk ratios (RRs) with 95% confidence intervals (CIs) for ticagrelor and clopidogrel. Results: Data from 6 RCTs comprising 21,827 elderly patients were extracted according to the eligibility criteria. There was no significant difference in the MACE outcome (incidence: 9.23% vs. 10.57%; RR = 0.95, 95% CI = 0.70–1.28, p = 0.72), MI (incidence: 5.40% vs. 6.23%; RR = 0.94, 95% CI= 0.69–1.27, p = 0.67), ST (incidence: 2.33% vs. 3.17%; RR = 0.61, 95% CI= 0.32–1.17, p = 0.13), and all-cause death (4.29% vs. 5.33%; RR = 0.86, 95% CI = 0.65–1.12, p = 0.25) for ticagrelor vs. clopidogrel, respectively. In addition, ticagrelor was not associated with a significant increase in the rate of major bleeding (incidence: 9.98% vs. 9.33%: RR = 1.37, 95% CI = 0.97–1.94, p = 0.07) vs. clopidogrel. Conclusions: This study did not find evidence that ticagrelor is significantly more effective or safer than clopidogrel in elderly patients with CHD.
Source Title: Journal of Cardiovascular Development and Disease
URI: https://scholarbank.nus.edu.sg/handle/10635/207178
ISSN: 23083425
DOI: 10.3390/jcdd8100123
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
jcdd-08-00123-v2.pdfPublished version2.05 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.